Ciwon daji na huhu ya kasance ƙalubalen lafiya a duniya, inda aka sanya shi a matsayin na biyu da aka fi gano cutar kansa. A shekarar 2020 kaɗai, an sami sabbin mutane sama da miliyan 2.2 da suka kamu da cutar a duk duniya. Ciwon daji na huhu wanda ba ƙaramin ƙwayar halitta ba ne (NSCLC) yana wakiltar sama da kashi 80% na duk waɗanda aka gano suna da cutar kansar huhu, wanda hakan ke nuna buƙatar gaggawa ta dabarun magani masu inganci da aka tsara.
Sauye-sauyen EGFR sun bayyana a matsayin ginshiƙi a cikin maganin da aka keɓance na NSCLC. Magungunan hana EGFR tyrosine kinase (TKIs) suna ba da wata hanya mai juyi ta hanyar toshe siginar da ke haifar da ciwon daji, hana ci gaban ciwon daji, da kuma haɓaka mutuwar ƙwayoyin cutar kansa - duk yayin da suke rage lalacewar ƙwayoyin lafiya.
Manyan jagororin asibiti, ciki har da NCCN, yanzu sun ba da umarnin gwajin maye gurbin EGFR kafin fara maganin TKI, don tabbatar da cewa marasa lafiya da suka dace sun sami magungunan da suka dace tun daga farko.
Sauye-sauyen EGFR sun bayyana a matsayin ginshiƙi a cikin maganin da aka keɓance na NSCLC. Magungunan hana EGFR tyrosine kinase (TKIs) suna ba da wata hanya mai juyi ta hanyar toshe siginar da ke haifar da ciwon daji, hana ci gaban ciwon daji, da kuma haɓaka mutuwar ƙwayoyin cutar kansa - duk yayin da suke rage lalacewar ƙwayoyin lafiya.
Manyan jagororin asibiti, ciki har da NCCN, yanzu sun ba da umarnin gwajin maye gurbin EGFR kafin fara maganin TKI, don tabbatar da cewa marasa lafiya da suka dace sun sami magungunan da suka dace tun daga farko.
Gabatar da Kayan Gano Canjin Halittar Dan Adam na EGFR 29 (Fluorescence PCR)
Gano Daidaito don Shawarwarin Jiyya Mai Inganci
Kayan gano EGFR na Macro & Micro-Test yana ba da damar gano manyan maye gurbi guda 29 cikin sauri da daidaito a cikin exons 18-21 a cikin ƙwayoyin halitta da na ruwa - yana ba wa likitoci damar daidaita magani cikin kwarin gwiwa.
Me Yasa ZabiGwajin Macro & Micro'sKayan Gwaji na EGFR?
Kayan aikin yana gano maye gurbi guda 29 na kwayar halittar EGFR a cikin exons 18-21 daga samfuran nama ko jini na marasa lafiya na NSCLC, wanda ke rufe wuraren da magani ke shafar su da kuma wuraren da za a iya jure su don jagorantar amfani da magunguna da aka yi niyya kamar gefitinib da osimertinib.
- 1. Ingantaccen Fasaha ta ARMS: Ingantaccen ARMS tare da ingantaccen kayan haɓaka lasisi don ƙarin takamaiman aiki;
- 2. Inganta Enzymatic: Yana rage asalin daji ta hanyar narkewar enzymatic, inganta daidaiton ganowa da rage fadadawa mara takamaiman saboda babban asalin kwayoyin halitta;
- 3. Toshewar Zafin Jiki: Yana ƙara takamaiman matakan zafin jiki a cikin tsarin PCR, yana rage rashin daidaito da kuma ƙara daidaiton ganowa;
- 4. Babban Jin Daɗi: Yana gano maye gurbi ƙasa da kashi 1%;
- 5. Babban Daidaito: Kulawa ta ciki da kuma enzyme na UNG don rage sakamakon ƙarya;
- 6. Inganci: Sakamakon da aka samu a cikin mintuna 120
- 7. Tallafin Samfura Biyu - An inganta shi don samfuran nama da jini, yana ba da sassauci a aikin asibiti
- 8. Dacewa mai faɗi: Ya dace sosai da kayan aikin PCR na yau da kullun a kasuwa;
- 9. Rayuwar shiryayye: watanni 12.
Jagorar Jagora tare da Kwarin gwiwa
Kayan aikin yana taimakawa wajen haɓaka sakamakon asibiti da kuma ci gaba da juriya tare da mahimmancin ji da sauye-sauyen juriya.
Faɗaɗa Fayil ɗinka na Incology na Daidaitacce
Bincika cikakken jerin hanyoyin magance maye gurbi na KRAS, BRAF, ROS1, ALK, BCR-ABL, TEL-AML1, da ƙari—duk an tsara su ne don tallafawa cikakken kulawar da ke da alaƙa da alamar halitta.
Ƙara koyo:https://www.mmtest.com/oncology/
Contact our team: marketing@mmtest.com
Lokacin Saƙo: Satumba-23-2025

